Contact:

Karen Whelan, Public Relations & Practice Marketing Specialist

508-787-1461

kwhelan@optos.com

Optos Launches V2® Vantage at Optometry’s Meeting™

28.06.2007

MARLBOROUGH, MA, June 28, 2007 – Optos, a leading medical technology company for the design, development, manufacturing, and marketing of retinal imaging devices, will introduce the latest version of its proprietary operating software – V2® Vantage – at the American Optometric Association’s (AOA) Optometry’s Meeting™ taking place in Boston, MA, June 28 – June 30, 2007.

“The introduction of V^2® Vantage delivers on a key promise within our customer partnership agreements to keep our customers on the leading edge of retinal imaging technology,” said Thomas W. Butts, Chief Executive Officer, Optos plc. “We expect V^2® Vantage to be particularly helpful to our customers in secondary care who are performing the optomap® plus Medical Retinal Exam, which is a reimbursable exam and enables practitioners to clearly monitor known conditions.”

Optos V^2® Vantage is now be available to all new Partners and is currently being rolled out to the Optos customer base. The new software offers many new innovative clinical advancements that will be beneficial to both the practitioner and patient. The new features include: 3D Wrap™ Patient Orientation Tool, ResMax™ High Resolution Enhancement for Central Pole, Practice Performance Statistics, Targeted Ophthalmoscopy Mode, and more.

“The new features of the V^2® Vantage operating software package have been particularly useful in my clinical practice,” stated Kim Castleberry, OD, Plano Eye Associates. “Since the new ResMax™ feature produces an image with resolution increased by approximately 10-15%, the software helps document pathology to monitor disease progression over time.”

Optos will host key educational activities to explore the exciting new features of V^2® Vantage including the Optos Academy workshop series for Partners and interested doctors which highlights techniques and best practices created to enable clinicians to achieve the highest level of success with the optomap® Retinal Exam. There will be three sessions of the Optos Academy including: Thursday, June 28 at 5:30 pm, Friday, June 29 at 12:30 pm, and Saturday, June 30 at 12:15 pm. Each session will feature, “A Beta Test Site User’s Experience,” by Kim Castleberry, OD, Plano Eye Associates, in which he will discuss his experience with the new software. In addition, “Overview of the Newest Software Release, V^2® Vantage,” will be given by Dave Iannetta, MBA, Business Manager, Optometry, Optos.

Optos will sponsor, “Comprehensive Retinal Update,” #2215 – on Friday, June 29, from 2:00 pm to 5:00 pm. The experts will discuss a myriad of issues ranging from caring for patients with diabetes by Dr. Jeffry Gerson, retinal disease detection and management by Dr. William Jones, and coding and reimbursement for retinal and vitreal conditions by Dr. Kim Castleberry.

Representatives from Optos will be at its booth throughout Optometry’s Meeting™ to meet with Optos Partners as well as educate attendees on the new features of V^2® Vantage. Booth, #905, visitors will receive a complimentary optomap® Retinal Exam and learn how this innovative technology – used by more than 2,500 eye care practitioners worldwide – helps with the detection and diagnosis of both eye and non-eye related conditions.

Note to Editors

Optos plc is a leading and rapidly growing medical technology company for the design, development, manufacturing and marketing of devices that image the retina, the light-sensitive area at the back of the eye. Optos' platform technology is the Panoramic200 Scanning Laser Ophthalmoscope device - known as the P200. In a quarter of a second the P200 device produces a high resolution image of up to 200 degrees or approximately 82 percent of the retina in a single capture. The image - branded the optomap® Retinal Exam - provides eye care practitioners with clinically useful information that facilitates the early detection of disorders and diseases evidenced in the retina, such as glaucoma, diabetic retinopathy and age-related macular degeneration. Retinal imaging can also indicate evidence of non-eye or systemic diseases such as diabetes, hypertension and certain cancers. The Company has gained regulatory clearance (CE and FDA 510(k)) to market a second device - P200MA. Optos’ technology provides an unequalled combination of wide-field retinal imaging, speed and convenience for both practitioner and patient and can help save sight and save lives.

Optos estimates that its P200 device is targeting a recurring US$2 billion market opportunity. As at 30 September 2006 Optos had 232 employees serving 2,593 customers in the Company’s existing markets, currently the USA, Canada, UK and Germany. Optos plc is headquartered in Dunfermline, Scotland and was admitted to the Main Market of the London Stock Exchange on 15 February 2006 trading under the symbol OPTS.

Optos is incorporated in Scotland under the Companies Act 1985 with registered number SC139953. The Company maintains its Registered Office at Queensferry House, Carnegie Business Campus, Dunfermline, Scotland KY11 8GR United Kingdom.